A Real World Experience of Using First-Line Sunitinib or Pazopanibin in Canadian Patients With Metastatic Renal Cell Carcinoma (mRCC)

Trial Profile

A Real World Experience of Using First-Line Sunitinib or Pazopanibin in Canadian Patients With Metastatic Renal Cell Carcinoma (mRCC)

Completed
Phase of Trial: Phase IV

Latest Information Update: 30 Nov 2016

At a glance

  • Drugs Pazopanib (Primary) ; Sunitinib (Primary)
  • Indications Renal cell carcinoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 30 Nov 2016 New trial record
    • 11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top